Stryker Corporation $SYK Stake Increased by Evelyn Partners Investment Management LLP

Evelyn Partners Investment Management LLP lifted its holdings in Stryker Corporation (NYSE:SYK) by 4.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 267,314 shares of the medical technology company’s stock after buying an additional 12,014 shares during the quarter. Stryker accounts for 2.6% of Evelyn Partners Investment Management LLP’s portfolio, making the stock its 10th biggest holding. Evelyn Partners Investment Management LLP’s holdings in Stryker were worth $93,953,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. VanderPol Investments L.L.C. boosted its stake in shares of Stryker by 1.4% in the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after buying an additional 28 shares in the last quarter. Rossby Financial LCC boosted its stake in shares of Stryker by 6.6% in the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after buying an additional 28 shares in the last quarter. Stonebridge Capital Advisors LLC boosted its stake in shares of Stryker by 0.4% in the third quarter. Stonebridge Capital Advisors LLC now owns 7,198 shares of the medical technology company’s stock valued at $2,661,000 after buying an additional 29 shares in the last quarter. Tcfg Wealth Management LLC boosted its stake in shares of Stryker by 2.7% in the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after buying an additional 29 shares in the last quarter. Finally, Mechanics Financial Corp boosted its stake in shares of Stryker by 1.2% in the fourth quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock valued at $864,000 after buying an additional 30 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have commented on the company. Needham & Company LLC decreased their target price on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Evercore set a $355.00 target price on Stryker in a research report on Friday, May 1st. Barclays decreased their target price on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. BTIG Research decreased their target price on Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $465.00 target price on shares of Stryker in a research report on Wednesday, March 4th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $395.33.

Insiders Place Their Bets

In other Stryker news, VP M Kathryn Fink sold 3,500 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the sale, the vice president directly owned 177 shares in the company, valued at $50,170.65. This represents a 95.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 323,264 shares of company stock worth $100,659,489 over the last three months. 4.60% of the stock is owned by insiders.

Stryker Stock Performance

Stryker stock opened at $312.14 on Friday. The firm has a market capitalization of $119.66 billion, a P/E ratio of 36.13, a PEG ratio of 1.97 and a beta of 0.78. The stock has a fifty day moving average price of $316.40 and a 200 day moving average price of $343.97. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio is currently 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.